Treatment of Advanced or Metastatic NSCLC with MET Exon 14 Skipping Mutation

Advanced and metastatic non-small cell lung cancer (NSCLC) is not a single disease. When molecular profiling identifies a MET exon 14 skipping mutation, it defines a distinct subpopulation with a recognised therapeutic vulnerability — one that changes first-line management.

MET exon 14 skipping mutations occur in approximately 3%–4% of lung adenocarcinomas and in roughly 2% of other NSCLC histologies. Their presence is associated with responsiveness to a specific class of oral receptor tyrosine-kinase inhibitors, making upfront molecular testing critical to identifying eligible patients.

First-Line Approach — Partial Overview

Guideline-recommended management for this mutation-defined population centres on first-line targeted oral therapy. Two agents are categorised as preferred options; a third is considered useful in certain circumstances. Full eligibility criteria, sequencing guidance, and regimen details are in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

MET exon 14 skipping mutations occur in 3% to 4% of patients with lung adenocarcinoma and approximately 2% of patients with other NSCLC histologies.
The presence of METex14 skipping mutation is associated with responsiveness to oral HGF receptor (c-Met) TKIs.
The Panel recommends capmatinib, tepotinib, or crizotinib as first-line targeted therapy options for patients with advanced or metastatic NSCLC and a MET exon 14 skipping mutation.
Capmatinib and tepotinib are categorized as preferred, while crizotinib is considered "Useful in certain circumstances."

View source ↗